Literature DB >> 19608940

Planning for posttrial access to antiretroviral treatment for research participants in developing countries.

Seema Shah1, Stacey Elmer, Christine Grady.   

Abstract

Despite recognition of the importance of posttrial access to antiretroviral therapy (ART), the implementation process has not been studied. We examined whether the National Institutes of Health (NIH) guidance document was being implemented in NIH-funded ART trials conducted in developing countries between July 2005 and June 2007. All of the 18 studies we identified had posttrial access plans for trial participants. More than 70% had specific mechanisms for posttrial access, but none guaranteed long-term sponsor funding after the trials. The plans reflected variation in local contexts and the uncertainty of predicting local conditions in the long term. The strength of the NIH guidance document may be that it encourages investigators to formulate plans in advance and to work with other stakeholders to provide access to ART.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608940      PMCID: PMC2724444          DOI: 10.2105/AJPH.2008.157982

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  6 in total

1.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  J Postgrad Med       Date:  2002 Jul-Sep       Impact factor: 1.476

2.  The ethics of research related to health care in developing countries.

Authors:  J R McMillan; C Conlon
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

3.  Justice and the human development approach to international research.

Authors:  Alex John London
Journal:  Hastings Cent Rep       Date:  2005 Jan-Feb       Impact factor: 2.683

4.  HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Authors:  Somnuek Sungkanuparph; Sasisopin Kiertiburanakul; Anucha Apisarnthanarak; Kumthorn Malathum; Boonmee Sathapatayavongs
Journal:  Int J STD AIDS       Date:  2007-12       Impact factor: 1.359

5.  Ethical considerations related to the provision of care and treatment in vaccine trials.

Authors:  D Tarantola; R Macklin; Z H Reed; M P Kieny; S Osmanov; M Stobie; C Hankins
Journal:  Vaccine       Date:  2007-03-30       Impact factor: 3.641

6.  Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

Authors:  Andrew N Phillips; Andrew Carr; Jacquie Neuhaus; Fehmida Visnegarwala; Ronald Prineas; William J Burman; Ian Williams; Fraser Drummond; Daniel Duprez; Waldo H Belloso; Frank-Detlef Goebel; Birgit Grund; Angelos Hatzakis; Jose Vera; Jens D Lundgren
Journal:  Antivir Ther       Date:  2008
  6 in total
  8 in total

1.  Ethical imperative of posttrial access to antiretroviral treatment.

Authors:  Onyekachi Sunny Onyeabor
Journal:  Am J Public Health       Date:  2010-04-15       Impact factor: 9.308

2.  Ethical issues in HIV prevention research with people who inject drugs.

Authors:  Jeremy Sugarman; Scott M Rose; David Metzger
Journal:  Clin Trials       Date:  2013-10-14       Impact factor: 2.486

Review 3.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

4.  An Ethical Imperative to Ensure Uninterrupted HIV Care Following Therapeutic Trials: One Experience in Peru.

Authors:  Katherine Garcia-Rosales; Karin Sosa Barbaran; Jessica Rios; Delia Pinto-Santini; Maria Del Rosario Leon; Jorge A Gallardo-Cartagena; John MacRae; Mey Leon; Javier Valencia-Huamaní; Esmelda Montalban; Pedro Gonzales; Ann Duerr; Javier R Lama; Rachel Bender Ignacio
Journal:  AIDS Patient Care STDS       Date:  2022-06       Impact factor: 5.944

5.  The patient's safety and access to experimental drugs after the termination of clinical trials: regulations and trends.

Authors:  Ricardo Eccard da Silva; Angélica Amorim Amato; Thiago do Rego Sousa; Marta Rodrigues de Carvalho; Maria Rita Carvalho Garbi Novaes
Journal:  Eur J Clin Pharmacol       Date:  2018-05-12       Impact factor: 2.953

Review 6.  The potential exploitation of research participants in high income countries who lack access to health care.

Authors:  Rafael Dal-Ré; Annette Rid; Ezekiel Emanuel; David Wendler
Journal:  Br J Clin Pharmacol       Date:  2016-02-29       Impact factor: 4.335

7.  Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review.

Authors:  Neema Sofaer; Daniel Strech
Journal:  Public Health Ethics       Date:  2011-07-11       Impact factor: 1.940

8.  Reciprocity-based reasons for benefiting research participants: most fail, the most plausible is problematic.

Authors:  Neema Sofaer
Journal:  Bioethics       Date:  2013-12-06       Impact factor: 1.898

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.